Table 2 Prevalence of anticholinergic burden score measured using KABS and ACB with and without including weak anticholinergics
Non-dementia (N = 57,712) | Dementia (N = 28,864) | |||||||
|---|---|---|---|---|---|---|---|---|
KABS | KABS-1 | ACB | ACB-1 | KABS | KABS-1 | ACB | ACB-1 | |
Anticholinergic exposure during 2–10 year before index year | ||||||||
Minimal (< 0.25) | 29,280 (50.7%) | 38,227 (66.2%) | 23,890 (41.4%) | 48,142 (83.4%) | 13,347 (46.2%) | 17,739 (61.5%) | 11,502 (39.9%) | 23,031 (79.8%) |
Low (0.25–1) | 22,060 (38.2%) | 16,555 (28.7%) | 24,785 (43.0%) | 8,176 (14.2%) | 11,556 (40.0%) | 9,167 (31.8%) | 12,433 (43.1%) | 4,854 (16.8%) |
Intermediate (1–2) | 5,136 (8.9%) | 2,488 (4.3%) | 7,447 (12.9%) | 1,188 (2.1%) | 3,045 (10.6%) | 1,630 (5.6%) | 3,954 (13.7%) | 830 (2.9%) |
High (≥2) | 1236 (2.1%) | 442 (0.8%) | 1590 (2.8%) | 206 (0.4%) | 916 (3.2%) | 328 (1.1%) | 975 (3.4%) | 149 (0.5%) |
Anticholinergic exposure during 5–10 year before index year | ||||||||
Minimal (< 0.25) | 32,424 (56.2%) | 40,272 (69.8%) | 27,297 (47.3%) | 50,009 (86.7%) | 15,283 (53.0%) | 19,174 (66.4%) | 13,566 (47.0%) | 24,226 (83.9%) |
Low (0.25–1) | 19,959 (34.6%) | 14,903 (25.8%) | 22,432 (38.9%) | 6,662 (11.5%) | 10,389 (36.0%) | 8,093 (28.0%) | 11,105 (38.5%) | 3,937 (13.6%) |
Intermediate (1–2) | 4,263 (7.4%) | 2128 (3.7%) | 6,539 (11.3%) | 862 (1.5%) | 2,482 (8.6%) | 1,333 (4.6%) | 3,372 (11.7%) | 588 (2.0%) |
High (≥2) | 1,066 (1.9%) | 409 (0.7%) | 1,444 (2.5%) | 179 (0.3%) | 710 (2.5%) | 264 (0.9%) | 821 (2.8%) | 113 (0.4%) |